Diagnostic Value of VEGF And Ki-67 Expression in Predicting Recurrence Risk in Ovarian Cancer

This article assesses the clinical and prognostic value of VEGF and Ki-67 immunohistochemical markers in patients diagnosed with ovarian cancer. A total of 130 patients treated at the Tashkent Regional Branch of the Republican Oncology and Radiology Center between 2018 and 2022 were included in the study. Expression of the markers was evaluated using H-score and percentage index methods. Results demonstrated that high levels of VEGF and Ki-67 expression were significantly associated with increased recurrence risk (p<0.001). Kaplan–Meier survival analysis and Cox regression confirmed the independent prognostic significance of these markers. The potential for developing an immunohistochemical prognostic panel to guide individualized therapeutic strategies and determine the necessity of adjuvant therapy is discussed.

Ҳали таржима қилинмаган